MarginsXMarginsX
Home › Markets › Health Care › TGTX

TG Therapeutics Inc. (TGTX)

TGTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$62.76
-2.71% on the day
Market cap
$9.5B
Mid cap
Revenue · 2025
$616.3M
+87.3% on 2024
Net income · 2025
$447.2M
72.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1001316/000143774926006133/0001437749-26-006133-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTGTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001001316
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$616.3M
Net income$447.2M
Operating income$123.3M
Net margin72.6%
Operating margin20.0%
Revenue growth+87.3%
Cash$79.1M
Total assets$1.1B
P/E (computed)21.2×
P/S (computed)15.4×

Warning signs

Cash runway
Cash-flow positive
$429.4M cash at September 30, 2026
Share count, 1 year
-4.8%
2025-10-31 to 2026-11-04 · -0.2% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$438K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$429.4M cash; operating cash flow $21.6M a quarter.Report 2026-09-30
Shares outstanding151,147,827 (2026-11-04); 158,759,451 a year earlier; 151,410,073 three years earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, New York, New York, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $438K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$259.9M$55.5M$45.2M$429.4M$745.6M$897.8M10-Q 2026-11-09
Q2 2026
2026-06-30
$240.3M$7.8M$39.3M$482.6M$745.4M$799.5M10-Q 2026-08-05
Q1 2026
2026-03-31
$204.9M$19.8M-$17.9M$442.2M$745.1M$700.3M10-Q 2026-05-06
Q4 2025
2025-12-31
$192.6M$23.0M$19.7M$79.1M$245.6M$616.3M10-K 2026-02-27
Q3 2025
2025-09-30
$161.7M$390.9M-$23.2M$74.1M$245.3M$531.9M10-Q 2026-11-09
Q2 2025
2025-06-30
$141.1M$28.2M$7.4M$129.1M$245.0M$454.1M10-Q 2026-08-05
Q1 2025
2025-03-31
$120.9M$5.1M-$28.7M$132.1M$244.7M$386.4M10-Q 2026-05-06
Q4 2024
2024-12-31
$108.2M$23.3M-$25.6M$179.9M$244.4M$329.0M10-K 2026-02-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM S-3ASR
S-3ASR2025-08-08
Latest annual report
FORM 10-K
10-K2026-02-27
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxy
FORM DEF 14A
DEF 14A2026-04-30

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+7.8%
1 month+18.7%
3 months+34.6%
Year to date+116.4%
1 year+108.4%
From 52-week high-1.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SMMTSummit Therapeutics Inc. Common Stock$11.82-16.47%$9.5B
SYRESpyre Therapeutics Inc.$99.37-4.45%$9.4B
MDGLMadrigal Pharmaceuticals Inc.$423.96-0.80%$9.8B
PRAXPraxis Precision Medicines Inc.$310.27-5.44%$8.7B
PTGXProtagonist Therapeutics Inc.$124.83-4.67%$8.1B
BMRNBioMarin Pharmaceutical Inc.$57.99+1.33%$11.2B
ALKSAlkermes plc$46.53-1.06%$7.8B
CORTCorcept Therapeutics Incorporated$69.22-5.10%$7.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier